Methylation of RUNX3 and RASSF1A and the risk of Malignancy in small solitary pulmonary nodules

Autor: Cui Xiangyu, Zhao Jinglan, Lu Ruizhen, Zhang Zhixue, Peng Chen, Huang Xiuying
Rok vydání: 2019
Předmět:
Adult
Male
0301 basic medicine
endocrine system
Lung Neoplasms
Biology
RUNX3 gene
lcsh:RC254-282
law.invention
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Western blot
law
Biopsy
Biomarkers
Tumor

medicine
Humans
Radiology
Nuclear Medicine and imaging

RASSF1A gene
Promoter Regions
Genetic

Polymerase chain reaction
Aged
Aged
80 and over

Solitary pulmonary nodule
DNA methylation
medicine.diagnostic_test
Tumor Suppressor Proteins
Solitary Pulmonary Nodule
Promoter
small solitary pulmonary nodule
General Medicine
Methylation
Middle Aged
Prognosis
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
medicine.disease
Molecular biology
digestive system diseases
Gene Expression Regulation
Neoplastic

Core Binding Factor Alpha 3 Subunit
030104 developmental biology
Oncology
chemistry
030220 oncology & carcinogenesis
Female
DNA
Follow-Up Studies
Zdroj: Journal of Cancer Research and Therapeutics, Vol 15, Iss 4, Pp 899-903 (2019)
ISSN: 0973-1482
DOI: 10.4103/jcrt.jcrt_790_18
Popis: Background: This study aimed to evaluate the methylation of RUNX3 and RASSF1A gene promoter regions as a marker to distinguish between benign and malignant of small solitary pulmonary nodule (SPN) ≤10 mm in size. Materials and Methods: A total of 147 patients with pathologically confirmed SPNs were enrolled. DNA samples were extracted from biopsy tissues or serum. Methylation of RUNX3 and RASSF1A gene promoter regions was detected by the methylation-specific polymerase chain reaction. The expression of RUNX3 and RASSF1A in SPN tissues was detected by western blot. Results: Of the 147 patients, 89 had benign SPNs and 58 had malignant SPNs. The rate of serum RUNX3 and RASSF1A gene methylation in malignant SPNs was significantly higher than that in benign SPNs (65.5% vs. 12.3%, and 67.2% vs. 10.1%, respectively; P < 0.05). The expression of RUNX3 and RASSF1A in malignant SPN tissues was lower than that in benign SPN tissues. The hypermethylation status of RUNX3 or RASSF1A genes was not significantly associated with age, gender, and smoking. Conclusions: The methylation level of the RUNX3 and RASSF1A gene promoter regions is a promising marker for assessing SPNs.
Databáze: OpenAIRE
Nepřihlášeným uživatelům se plný text nezobrazuje